This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH PLAINFIELD, N.J.,
June 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that
Shane Kovacs, Chief Financial Officer, has received the 2014 Deal of the Year Award from the New Jersey Technology Council (NJTC). The Deal of the Year Award is part of the annual NJTC CFO Awards Breakfast, which recognizes the accomplishments of financial executives from the region's diverse technology community.
"I am honored to receive the CFO – Deal of the Year Award. When I joined PTC last year, we had just closed on a successful private placement and were about to kick-off what would also prove to be a very successful IPO. The combination of PTC's novel science, late-stage assets, a promising pipeline and a focus on rare and neglected disorders drew strong interest from institutional investors for both our IPO and our subsequent follow-on equity offering," said
Shane Kovacs, Chief Financial Officer of PTC Therapeutics, Inc. "The combined capital we raised will allow PTC to continue to advance the clinical development of our pipeline candidates and to prepare for the anticipated launch of Translarna
™ for the treatment of Duchenne muscular dystrophy across
Europe. I am excited to be a part of the PTC team at such a transformational time in the history of the company."
"We are very proud for Shane to be recognized as an accomplished CFO. He joined the company a year ago and has been a valuable addition to the team. His broad depth of experience gives him the ability to work cross-functionally at PTC and help shape the strategic direction of our company," stated
Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, Inc. "Shane's expertise will be influential as PTC prepares to launch its first drug in
Europe and build-out a commercial organization."
Prior to joining PTC, Mr. Kovacs served as Managing Director, Health Care Investment Banking at Credit Suisse. In this capacity, he focused on advising life science companies on transactions ranging from equity and debt financings to mergers and acquisitions.